Efficacy of therapy with Berodual N by means of small spacers in patients with acute exacerbations of obstructive pulmonary diseases
https://doi.org/10.18093/0869-0189-2005-0-6-86-90
Abstract
The randomized controlled single hospital centre study assessed the efficacy of therapy with Berodual N (fenoterol / ipratropium) delivered by means of small spacers in patients with acute exacerbations of obstructive pulmonary diseases. Inclusion criteria were acute exacerbation of COPD or asthma, age 18–75 yrs, FEV1 30–60 %, no need for respiratory support. 61 patients with COPD or asthma (M : F = 37 : 24, mean age 59 ± 8 yrs; FEV1 — 40 ± 11 %, SpO2 = 94 ± 2 %) were randomized to Berodual N 2 inhalations via MDI (n = 31) or Berodual N 2 inhalations via spacer-MDI (n = 30). Therapy with Berodual N in both groups of patients led to statistically significant improvement in FEV1, FVC and IC, and to decrease in respiratory rate and dispnea. Therapy with Berodual N via spacer-MDI resulted in more significant improvement of FVC and IC (difference between groups after 0.5 and 1 h after inhalation: р < 0.05). Dyspnea score also improved more significantly in patients received Berodual N via spacer-MDI (difference between groups after 0.5 and 1 h after inhalation: р < 0.05). The incidence of adverse events was similar between the groups. Conclusion: in patients with acute exacerbations of obstructive pulmonary diseases therapy with Berodual N by means of small spacers and MDI is more effective in comparison with MDI only.
About the Authors
S. N. Avdeev
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
G. S. Nuralieva
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
S. Z. Batin
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
A. G. Chuchalin
ФГУ НИИ пульмонологии Росздрава
Russian Federation
Russian Federation
References
1. Global strategy for asthma management and prevention NHLBI / WHO workshop report: NIH publication № 023659. The updated 2004 report is available on www.ginasthma.com.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Publication number 2701. The updated 2005 report is available on www.goldcopd.com.
3. International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. Lancet 1998; 351: 1225–1232.
4. Chen J.C., Mannino D.M. Worldwide epidemiology of chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 1999; 5: 93–99.
5. Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American college of chest physicians / American college of asthma, allergy, and immunology. Chest 2005; 127: 335–371.
6. Zanon P. Inhalation anti-asthma therapy with spacers: technical aspects. Monaldi Arch. Chest Dis. 1994; 49: 258–264.
7. Terzano C. Pressurized metered dose inhalers and add-on devices. Pulm. Pharmacol. Ther. 2001; 14: 351–366.
8. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Eur. Respir. J. 1993; 6 (suppl. 16): 5–40.
9. Gift A.G. Validation of a vertical visual analogue scale as a measure of clinical dyspnea. Rehab. Nurs. 1989; 14: 313–325.
10. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 10 (5): 255–261.
11. Newman S.P., Millar A.B., Lennard-Jones T.R. et al. Improvement of pressurised aerosol deposition with Nebuhaler spacer device. Thorax 1984; 39:935–941.
12. Cochrane M.G., Bala M.V., Downs K.E. et al. Inhaled corticosteroids for asthma therapy. Patient compliance, devices, and inhalation technique. Chest 2000; 117: 542–550.
13. Pierart F., Wildhaber J.H., Vrancken I. et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur. Respir. J. 1999; 13: 673–678.
14. Newman S.P. Aerosol generators and delivery systems. Respir. Care 1991; 36: 939–951.
15. Agertoft L., Pedersen S. Influence of spacer device on drug delivery to young children with asthma. Arch. Dis. Child. 1994; 71: 217–220.
16. Dolovich M., Ruffin R., Corr D., Newhouse M.T. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest 1983; 84: 36–41.
17. Wilkes W., Fink J., Dhand R. Selecting an accessory device with a metered-dose inhaler: variable influence of accessory devices on fine particle dose, throat deposition, and drug delivery with asynchronous actuation from a metered-dose inhaler. J. Aerosol Med. 2001; 14: 351–360.
18. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542–549.
19. Черняк А.В., Авдеев С.Н., Пашкова Т.Л., Айсанов З.Р. Бронходилатационный тест у больных с хронической обструктивной болезнью легких. Пульмонология 2003; 1: 50–56.
20. Авдеев С.Н. Роль легочной гиперинфляции в патогенезе ХОБЛ. Эффективность поддерживающей терапии в уменьшении легочной гиперинфляции. Пульмонология 2004; 6: 101–110.
21. Tavares F.M.B., Correa da Silva L.C., Rubin A.S. Measuring forced expiratory volume in one second alone is not an accurate method of assessing response to bronchodilators in chronic obstructive pulmonary disease. J. Bras. Pneumol. 2005; 31: 407–414.
Review
For citations:
Avdeev S.N., Nuralieva G.S., Batin S.Z., Chuchalin A.G. Efficacy of therapy with Berodual N by means of small spacers in patients with acute exacerbations of obstructive pulmonary diseases. PULMONOLOGIYA. 2005;(6):86-90. (In Russ.) https://doi.org/10.18093/0869-0189-2005-0-6-86-90
Views:
438
Email this article 